Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones

Biochemical Pharmacology

Volumn 92, Issue 4, 2014, Pages 627-641

  Schepetkin, Igor A ^a   Kirpotina, Liliya N ^a   Khlebnikov, Andrei I ^b,c   Cheng, Ni ^d   Ye, Richard D ^d   Quinn, Mark T ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b ALTAI STATE TECHNICAL UNIVERSITY   (Russian Federation)

^c NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antagonist; Ca2+ mobilization; Formyl peptide receptor; Isoflavone; Molecular modeling; Neutrophil

Indexed keywords

2 METHYL 3 (1 METHYL 1H BENZIMIDAZOL 2 YL) 4 OXO 4H CHROMEN 7 YL FURAN 2 CARBOXYLATE; 3 (2 CHLOROPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL FURAN 2 CARBOXYLATE; 3 (2 CHLOROPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL THIOPHENE 2 CARBOXYLATE; 3 (2 METHOXYPHENYL) 2 METHYL 4 OXO 4H CHROMEN 7 YL FURAN 2 CARBOXYLATE; 3 (2 METHOXYPHENYL) 2 METHYL 4 OXO 4H CHROMEN 7 YL THIOPHENE 2 CARBOXYLATE; 3 (2 METHOXYPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL 2 FUROATE; 3 (2 METHOXYPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL 2 METHYLPROPANOATE; 3 (2 METHOXYPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL BENZOATE; 3 (2 METHOXYPHENYL) 4 OXO 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL CYCLOPROPANECARBOXYLATE; 4 OXO 3 PHENYL 2 (TRIFLUOROMETHYL) 4H CHROMEN 7 YL THIOPHENE 2 CARBOXYLATE; 6 ETHYL 2 METHYL 3 (1 METHYL 1H BENZIMIDAZOL 2 YL) 4 OXO 4H CHROMEN 7 YL ACETATE; 7 HYDROXY ISOFLAVONE; AFRORMOSIN; BIOCHANIN A; CHEMOKINE RECEPTOR CXCR1; CHROMONE DERIVATIVE; DAIDZEIN; FORMONONETIN; FORMYLPEPTIDE RECEPTOR LIKE 1; FORMYLPEPTIDE RECEPTOR LIKE 1 ANTAGONIST; GENISTEIN; ISOFLAVONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; [6 HEXYL 2 METHYL 3 (1 METHYL 1H BENZIMIDAZOL 2 YL) 4 OXO 4H CHROMEN 7 YL ACETATE]; FORMYLPEPTIDE RECEPTOR; FPR1 PROTEIN, HUMAN;

2 METHYL 4 OXO 3 PHENYL 4H CHROMEN 7 YL FURAN 2 CARBOXYLATE; ANIMAL CELL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; IC50; MOLECULAR MODEL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHARMACOPHORE; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CELL CULTURE; CHEMICAL STRUCTURE;

BINDING, COMPETITIVE; CELLS, CULTURED; CHROMONES; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOFLAVONES; MODELS, MOLECULAR; RECEPTORS, FORMYL PEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84912104439     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.027     Document Type: Article

References (80)

1. Gao JL, Lee EJ, Murphy PM. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med 1999;189:657-62.
2. Liu M, Zhao J, Chen K, Bian X, Wang C, Shi Y, et al. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int Immunopharmacol 2012;14:283-8.
3. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, et al. International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009;61:119-61.
4. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006;17:501-19.
5. Gavins FN. Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury. Trends Pharmacol Sci 2010;31:266-76.
6. Li Y, Ye D. Molecular biology for formyl peptide receptors in human diseases. J Mol Med (Berl) 2013;91:781-9.
7. Schiffmann E, Corcoran BA, Wahl SM. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A 1975;72:1059-62.
8. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med 1982;155:264-75.
9. Cheng TY, Wu MS, Lin JT, Lin MT, Shun CT, Hua KT, et al. Formyl peptide receptor 1 expression is associated with tumor progression and survival in gastric cancer. Anticancer Res 2014;34:2223-9.
10. Stenfeldt AL, Karlsson J, Wennera˚s C, Bylund J, Fu H, Dahlgren C. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation 2007;30:224-9.
11. Rittner HL, Hackel D, Voigt P, Mousa S, Stolz A, Labuz D, et al. Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils. PLoS Pathog 2009;5:e1000362.
12. Cardini S, Dalli J, Fineschi S, Perretti M, Lungarella G, Lucattelli M. Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am J Respir Cell Mol Biol 2012;47:332-9.
13. Gschwendt M, Kittstein W, Marks F. The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro. Biochem Biophys Res Commun 1988;150:545-51.
14. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686-90.
15. Broekemeier KM, Pfeiffer DR. Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Biochemistry 1995;34:16440-49.
16. Zhou C, Zhou Y, Wang J, Feng Y, Wang H, Xue J, et al. V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins. Biochem J 2013;451:245-55.
17. Gavins FN, Hughes EL, Buss NA, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system. FASEB J 2012;26:4977-89.
18. Qin C, Buxton KD, Pepe S, Cao AH, Venardos K, Love JE, et al. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26). Br J Pharmacol 2013;168:238-52.
19. da Silva NG, Sampaio SC, Goncalves LR. Inhibitory effect of Crotalus durissus terrificus venom on chronic edema induced by injection of bacillus Calmette-Guerin into the footpad of mice. Toxicon 2013;63:98-103.
20. Gastardelo TS, Damazo AS, Dalli J, Flower RJ, Perretti M, Oliani SM. Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation. Am J Pathol 2009;174:177-83.
21. Hwang TL, Hung CH, Hsu CY, Huang YT, Tsai YC, Hsieh PW. Design and synthesis of tryptophan containing dipeptide derivatives as formyl peptide receptor 1 antagonist. Org Biomol Chem 2013;11:3742-55.
22. Hayashi R, Kitajima T, Mizuguchi H, Fujimoto M, Yamaguchi A, Koga S, et al. Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH. Bioorg Med Chem 2014;22:3824-8.
23. Colli S, Colombo S, Tremoli E, Stragliotto E, Nicosia S. Effects of tenoxicam on superoxide anion formation, beta-glucuronidase release and fMLP binding in human neutrophils: comparison with other NSAIDs. Pharmacol Res 1991;23:367-79.
24. Young SM, Bologa C, Prossnitz ER, Oprea TI, Sklar LA, Edwards BS. High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen 2005;10:374-82.
25. Stenfeldt AL, Karlsson J, Wenneras C, Bylund J, Fu H, Dahlgren C. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Biochem Pharmacol 2007;74:1050-6.
26. Edwards BS, Bologa C, Young SM, Balakin KV, Prossnitz ER, Savchuck NP, et al. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol 2005;68:1301-10.
27. Young SM, Bologa CM, Fara D, Bryant BK, Strouse JJ, Arterburn JB, et al. Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. Cytometry A 2009;75:253-63.
28. Unitt J, Fagura M, Phillips T, King S, Perry M, Morley A, et al. Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett 2011;21:2991-7.
29. Morley AD, Cook A, King S, Roberts B, Lever S, Weaver R, et al. Discovery of pyrazoles as novel FPR1 antagonists. Bioorg Med Chem Lett 2011;21:6456-60.
30. Morley AD, King S, Roberts B, Lever S, Teobald B, Fisher A, et al. Lead optimisation of pyrazoles as novel FPR1 antagonists. Bioorg Med Chem Lett 2012;22:532-6.
31. Pinilla C, Edwards BS, Appel JR, Yates-Gibbins T, Giulianotti MA, Medina-Franco JL, et al. Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol 2013;84:314-24.
32. Cevik-Aras H, Kalderen C, Jenmalm Jensen A, Oprea T, Dahlgren C, Forsman H. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol 2012;83:1655-62.
33. Schepetkin IA, Khlebnikov AI, Giovannoni MP, Kirpotina LN, Cilibrizzi A, Quinn MT. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition. Curr Med Chem 2014;21:1478-504.
34. Kirpotina LN, Khlebnikov AI, Schepetkin IA, Ye RD, Rabiet MJ, Jutila MA, et al. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol 2010;77:159-70.
35. Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT. High-throughput screening for small-molecule activators of neutrophils: Identification of novel N-formyl peptide receptor agonists. Mol Pharmacol 2007;71:1061-74.
36. Siemsen DW, Malachowa N, Schepetkin IA, Whitney AR, Kirpotina LN, Lei B, et al. Neutrophil isolation from nonhuman species. Methods Mol Biol 2014;1124:19-37.
37. Cheeseright T, Mackey M, Rose S, Vinter A. Molecular field technology applied to virtual screening and finding the bioactive conformation. Expert Opin Drug Discov 2007;2:131-44.
38. Cheeseright TJ, Mackey MD, Scoffin RA. High content pharmacophores from molecular fields: a biologically relevant method for comparing and understanding ligands. Curr Comput Aided Drug Des 2011;7:190-205.
39. Schepetkin IA, Kirpotina LN, Khlebnikov AI, Leopoldo M, Lucente E, Lacivita E, et al. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2. Biochem Pharmacol 2013;85:404-16.
40. Vinter JG. Extended electron distributions applied to the molecular mechanics of some intermolecular interactions. J Comput Aided Mol Des 1994;8:653-68.
41. Cheeseright T, Mackey M, Rose S, Vinter A. Molecular field extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 2006;46:665-76.
42. Movitz C, Brive L, Hellstrand K, Rabiet MJ, Dahlgren C. The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1. J Biol Chem 2010;285:14338-45.
43. Khlebnikov AI, Schepetkin IA, Kirpotina LN, Brive L, Dahlgren C, Jutila MA, et al. Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model 2012;18:2831-43.
44. Strouse JJ, Young SM, Mitchell HD, Ye RD, Prossnitz ER, Sklar LA, et al. A novel fluorescent cross-reactive formylpeptide receptor/formylpeptide receptor-like 1 hexapeptide ligand. Cytometry A 2009;75:264-70.
45. Arterburn JB, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA. Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem 2009;9:1227-36.
46. Grinstein S, Furuya W. Chemoattractant-induced tyrosine phosphorylation and activation of microtubule-associated protein kinase in human neutrophils. J Biol Chem 1992;267:18122-25.
47. Torres M, Hall FL, O'Neill K. Stimulation of human neutrophils with formyl-methionyl-leucyl-phenylalanine induces tyrosine phosphorylation and activation of two distinct mitogen-activated protein-kinases. J Immunol 1993;150:1563-77.
48. Khlebnikov AI, Schepetkin IA, Quinn MT. Quantitative structure-activity relationships for small non-peptide antagonists of CXCR2: indirect 3D approach using the frontal polygon method. Bioorg Med Chem 2006;14:352-65.
49. Khlebnikov AI, Schepetkin IA, Quinn MT. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors. Eur J Med Chem 2010;45:5406-19.
50. Cazarolli LH, Zanatta L, Alberton EH, Figueiredo MS, Folador P, Damazio RG, et al. Flavonoids: prospective drug candidates. Mini Rev Med Chem 2008;8:1429-40.
51. Rusin A, Krawczyk Z, Grynkiewicz G, Gogler A, Zawisza-Puchalka J, Szeja W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim Pol 2010;57:23-34.
52. Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 2010;16:1801-12.
53. Gilbert ER, Liu D. Anti-diabetic functions of soy isoflavone genistein: mechanisms underlying its effects on pancreatic beta-cell function. Food Funct 2013;4:200-12.
54. Bandgar BP, Totre JV, Gawande SS, Khobragade CN, Warangkar SC, Kadam PD. Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents. Bioorg Med Chem 2010;18:6149-55.
55. Raju BC, Rao RN, Suman P, Yogeeswari P, Sriram D, Shaik TB, et al. Synthesis, structure-activity relationship of novel substituted 4H-chromen-1,2,3,4-tet-rahydropyrimidine-5-carboxylates as potential anti-mycobacterial and anticancer agents. Bioorg Med Chem Lett 2011;21:2855-9.
56. Khlebnikov AI, Schepetkin IA, Domina NG, Kirpotina LN, Quinn MT. Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. Bioorg Med Chem 2007;15:1749-70.
57. Lengyel J, Rimarcik J, Vaganek A, Klein E. On the radical scavenging activity of isoflavones: thermodynamics of O-H bond cleavage. Phys Chem Chem Phys 2013;15:10895-903.
58. Reiter E, Reiter E, Beck V, Medjakovic S, Jungbauer A. Isoflavones are safe compounds for therapeutical applications - evaluation of in vitro data. Gynecol Endocrinol 2009;25:554-80.
59. Wahajuddin Taneja I, Arora S, Raju KS, Siddiqui N. Disposition of pharmacologically active dietary isoflavones in biological systems. Curr Drug Metab 2013;14:369-80.
60. Douglas CC, Johnson SA, Arjmandi BH. Soy and its isoflavones: the truth behind the science in breast cancer. Anticancer Agents Med Chem 2013;13:1178-87.
61. Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr 2006;136:899-905.
62. Mizushina Y, Shiomi K, Kuriyama I, Takahashi Y, Yoshida H. Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cancer cell proliferation. Int J Oncol 2013;43:1117-24.
63. Ajdzanovic VZ, Milosevic V, Spasojevic IB. Glucocorticoid excess and disturbed hemodynamics in advanced age: the extent to which soy isoflavones may be beneficial. Gen Physiol Biophys 2012;31:367-74.
64. Luo LJ, Liu F, Lin ZK, Xie YF, Xu JL, Tong QC, et al. Genistein regulates the IL-1 beta induced activation of MAPKs in human periodontal ligament cells through G protein-coupled receptor 30. Arch Biochem Biophys 2012;522:9-16.
65. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol 2014;389:71-83.
66. Schepetkin IA, Khlebnikov AI, Giovannoni MP, Kirpotina LN, Cilibrizzi A, Quinn MT. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition. Curr Med Chem 2013;21:1478-504.
67. Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, et al. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol 2007;72:976-83.
68. Lin Y-L, Dai Z-K, Lin R-J, Chu K-S, Chen I-J, Wu J-R, et al. Baicalin, a flavonoid from Scutellaria baicalensis Georgi, activates large-conductance Ca2+-activated K+ channels via cyclic nucleotide-dependent protein kinases in mesenteric artery. Phytomedicine 2010;17:760-70.
69. Das A, Banik NL, Ray SK. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 2010;116:164-76.
70. Wang J-P, Hsu M-F, Ko H-H, Lin C-N. Stimulation of cellular free Ca2+ elevation and inhibition of store-operated Ca2+ entry by kazinol B in neutrophils. Naunyn-Schmiedeberg's Arch Pharmacol 2004;370:500-9.
71. Chen CY, Liaw CC, Chen YH, Chang WY, Chung PJ, Hwang TL. A novel immunomodulatory effect of ugonin U in human neutrophils via stimulation of phospholipase C. Free Radic Biol Med 2014;72:222-31.
72. Wang C, Lu H, Chen G, Yamashita K, Manabe M, Kodama H. Effect of S-(1,2-dicarboxyethyl) glutathione and S-(1,2-dicarboxyethyl) cysteine on the stimulus-induced superoxide generation and tyrosyl phosphorylation of proteins in human neutrophils. Clin Chem Lab Med 2002;40:1101-4.
73. Rotondo S, Krauze-Brzosko K, Manarini S, Martelli N, Pecce R, Evangelista V, et al. Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake. Br J Nutr 2008;99:240-7.
74. Kruk I, Aboul-Enein HY, Michalska T, Lichszteld K, Kladna A. Scavenging of reactive oxygen species by the plant phenols genistein and oleuropein. Luminescence 2005;20:81-9.
75. Yagi Y, Otani H, Ando S, Oshiro A, Kawai K, Nishikawa H, et al. Involvement of Rho signaling in PAR2-mediated regulation of neutrophil adhesion to lung epithelial cells. Eur J Pharmacol 2006;536:19-27.
76. Nitto T, Araki Y, Takeda Y, Sendo F. Pharmacological analysis for mechanisms of GPI-80 release from tumour necrosis factor-alpha-stimulated human neutrophils. Br J Pharmacol 2002;137:353-60.
77. Zen K, Reaves TA, Soto I, Liu Y. Response to genistein: assaying the activation status and chemotaxis efficacy of isolated neutrophils. J Immunol Methods 2006;309:86-98.
78. de Araujo Lopes A, Magalhaes TR, de Andrade Uchoa DE, Silveira ER, Azzolini AE, Kabeya LM, et al. Afrormosin, an isoflavonoid from Amburana cearensis A. C. Smith, modulates the inflammatory response of stimulated human neutrophils. Basic Clin Pharmacol Toxicol 2013;113:363-9.
79. Veitch NC. Isoflavonoids of the leguminosae. Nat Prod Rep 2013;30:988-1027.
80. Huang YC, Hwang TL, Yang YL, Wu SH, Hsu MH, Wang JP, et al. Acetogenin and prenylated flavonoids from Helminthostachys zeylanica with inhibitory activity on superoxide generation and elastase release by neutrophils. Planta Med 2010;76:447-53.